NCT00814736

A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate the Safety and Toleration of Single Dose Sildenafil in Subjects Receiving Chronic UK-369,0031

A Randomized, Double-Blinded, Placebo-Controlled, Two-Way Crossover Study to Investigate The Safety And Toleration Of Single Dose Sildenafil In Subjects Receiving Chronic UK-369,003.

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 22 (actual)
• Sponsor: Pfizer · Industry
• Sex: Male
• Age: 40 Years – 55 Years
• Healthy volunteers: Accepted

Summary

To investigate the safety and overall tolerability of co-administration two PDE5 inhibitors UK369,003 and sildenafil

Conditions

• Prostatic Hyperplasia
• Urinary Bladder, Overactive
• Erectile Dysfunction

Interventions

Type	Name	Description
DRUG	UK369,003	oral tablet, once a day
DRUG	sildenafil	single oral dose on day 14 or day 17
DRUG	sildenafil matching placebo	single oral dose on day 14 or day 17

Timeline

• Start date: 2008-08-01
• Primary completion: 2008-09-01
• Completion: 2008-09-01
• First posted: 2008-12-25
• Last updated: 2008-12-25

Locations

1 site across 1 country: Singapore